GlassScriptPhysician profile
Liza Chen
NPI 1043294275
$13,179.67
in general payments reported to CMS, 2019-2025
61 companies · $5,490 in 2025
The $5,490 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $1,089 · 2023: $2,639 · 2024: $3,860 · 2025: $5,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,611.74 |
| Education | $376.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,278.89 | 2022-2025 | Tecvayli, Darzalex, Carvykti |
| Daiichi Sankyo INC. | $1,017.77 | 2022-2025 | Injectafer, Enhertu, Vanflyta |
| Glaxosmithkline, LLC. | $1,002.91 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Sobi, INC | $844.82 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $787.96 | 2022-2025 | Calquence, Enhertu, Tagrisso |
| Pfizer INC. | $607.47 | 2022-2025 | |
| Exelixis INC. | $565.55 | 2022-2025 | Cabometyx |
| Astellas Pharma US INC | $536.66 | 2024-2025 | Vyloy, Padcev, Xtandi |
| Novartis Pharmaceuticals Corporation | $445.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $408.50 | 2022-2025 | Fruzaqla, Alunbrig, Iclusig |
| Eisai INC. | $392.01 | 2023-2025 | |
| Stemline Therapeutics INC. | $285.08 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $280.17 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $267.44 | 2023-2025 | |
| Seagen INC. | $262.39 | 2022-2023 | Tukysa, Adcetris |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $256.85 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $252.29 | 2022-2025 | Jakafi, Niktimvo, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $243.47 | 2022-2025 | Opdivo, Reblozyl |
| Celgene Corporation | $235.14 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
| Pharmaessentia USA Corporation | $215.53 | 2024-2025 | Besremi |
| Blueprint Medicines Corporation | $203.27 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $184.11 | 2024-2025 | Polivy, Phesgo, Tecentriq |
| Abbvie INC. | $176.53 | 2023-2025 | |
| Puma Biotechnology, INC. | $153.39 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $146.49 | 2022-2023 | Imbruvica, Epkinly |
| Karyopharm Therapeutics INC. | $143.65 | 2022-2024 | Xpovio |
| Adc Therapeutics America, INC. | $135.86 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $131.49 | 2022 | |
| Emd Serono, INC. | $123.70 | 2023-2025 | Tepmetko, Bavencio |
| Array Biopharma INC | $110.63 | 2024-2025 | Lorbrena, Braftovi, Mektovi |
| Beigene USA, INC. | $104.12 | 2024-2025 | Brukinsa |
| Caris Mpi, INC. | $99.86 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $96.89 | 2023-2025 | |
| Genmab U.S., INC. | $94.51 | 2024-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $92.56 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $92.22 | 2023-2024 | Libtayo |
| Amgen INC. | $88.22 | 2022-2023 | Blincyto, Kyprolis, Xgeva |
| Rigel Pharmaceuticals, INC. | $78.16 | 2023-2024 | Tavalisse, Rezlidhia |
| Sun Pharmaceutical Industries INC. | $61.24 | 2022-2024 | Yonsa |
| Agios Pharmaceuticals, INC. | $54.37 | 2024-2025 | Pyrukynd |
| Angiodynamics, INC. | $51.38 | 2021 | |
| Medtronic, INC. | $51.08 | 2021 | |
| Amag Pharmaceuticals, INC. | $48.40 | 2022 | |
| Recordati_rare_diseases_inc. | $45.92 | 2023-2024 | Sylvant |
| Alexion Pharmaceuticals, INC. | $41.20 | 2023-2024 | Ultomiris |
| Kyowa Kirin, INC. | $38.62 | 2022 | |
| Apellis Pharmaceuticals, INC. | $35.16 | 2023 | Empaveli |
| Syndax Pharmaceuticals, INC. | $32.82 | 2025 | |
| Geron Corporation | $29.65 | 2025 | Rytelo |
| Immunogen, INC. | $29.14 | 2023 | Elahere |
| Deciphera Pharmaceuticals INC. | $27.00 | 2025 | Qinlock, Romvimza |
| Fennec Pharmaceuticals, INC. | $25.31 | 2025 | Fyarro |
| Morphosys, US INC. | $23.26 | 2023 | Monjuvi |
| Gilead Sciences, INC. | $22.01 | 2023 | |
| Pharmacosmos Therapeutics INC. | $21.24 | 2022 | |
| Beone Medicines USA, INC. | $19.32 | 2025 | Brukinsa |
| Menarini Silicon Biosystems, INC. | $18.56 | 2025 | |
| Aadi Bioscience, INC. | $16.70 | 2023 | Fyarro |
| Coherus Oncology, INC. | $15.92 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.60 | 2023 | Tazverik |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.